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Abstract 
Despite decades of research many aspects of the biology of Mycobacterium tuberculosis 
remain unclear and this is reflected in the antiquated tools available to treat and prevent 
tuberculosis and consequently this disease remains a serious public health problem. 
Important discoveries linking M. tuberculosis’s metabolism and pathogenesis has 
renewed interest in this area of research. Previous experimental studies were limited to 
the analysis of individual genes or enzymes whereas recent advances in computational 
systems biology and high throughput experimental technologies now allows metabolism 
to be studied on a genome scale. Here we discuss the progress being made in applying 
system level approaches to studying the metabolism of this important pathogen.  
Introduction 
Mycobacterium tuberculosis is an unusual bacterial pathogen which has the remarkable 
ability to cause both acute life threatening disease and also clinically latent infections 
which can persist for the lifetime of the human host. Unlike many pathogens M. 
tuberculosis does not rely on the production of specific toxins to cause disease but rather 
the secret of this bacterium’s great success seems to be the ability to adapt and survive 
within the changing and adverse environment provided by the human host during the 
course of an infection. It is becoming apparent that key to this adaptation is the metabolic 
reprogramming of M. tuberculosis during both the acute and chronic phase of TB disease 
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and therefore a more complete understanding of mycobacterial metabolism remains a 
major goal of TB research.  
Whilst recent increases in research funding has progressed our understanding of the basic 
biology of M. tuberculosis this has not yet impacted on the global TB trends which 
remain at staggering levels. A possible reason why it has been difficult to translate basic 
research into effective strategies for combating tuberculosis is that TB research has until 
recently, focused on studying individual parameters in isolation which can consequently 
result in an overestimation of the importance of these factors. This effect may be 
particularly profound for a persistent pathogen such as M. tuberculosis which lacks 
classical virulence factors. The systems biology framework which investigates the 
dynamic interactions of many components provides an alternative and complementary 
strategy to the more traditional reductionist approaches to TB research. This methodology 
has started to be applied to the metabolism of M. tuberculosis on a genome scale and 
promises to drive biological discovery in the TB research field by providing scaffolding 
for the interpretation of “omic” scale datasets, directing hypothesis driven discovery and 
also assisting in the identification of novel drug targets.  
Metabolic model building 
The ultimate goal of system biology approaches to studying TB is to construct a complete 
model of infection incorporating both the pathogen and host, but this is currently 
infeasible as the information about the different components to be included in the model 
is lacking. Studies with other organisms have demonstrated that metabolism is, by far, the 
best understood cellular network and is thereby an excellent starting point for a systems-
based approach [6;11;14].  
Ideally metabolic models would describe the dynamic behavior of M. tuberculosis 
metabolism using rate equations however this would require detailed kinetic parameters 
(e.g. Km, Vmax and substrate/product concentrations) of all the participating reactions. 
This approach has the advantage of being capable of modeling dynamic systems but its 
major disadvantage is that the values of the parameters required are difficult to measure 
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and are unavailable on a genome scale even for the extensively studied Escherichia coli. 
Kinetic models have therefore only been applied to examine the dynamics of small well-
defined systems, such as glycolysis in Escherichia coli [4]. The alternative is to use 
constraints-based modeling approaches, such as flux balance analysis (FBA). Instead of 
modeling dynamic states, FBA models steady state systems where concentrations of 
metabolites are held constant. In this situation, metabolic fluxes obey simple 
stoichiometric relationships. For instance, the stoichiometric equation, 1 A + 2B -> 1 C, 
implies that one mole of A plus 2 moles of B will be converted to 1 mole of C. In FBA, 
the predicted rate (flux) at which this conversion takes place is constrained to a set of 
values that are consistent with measured parameters, such as substrate utilization or 
biomass production rates. For instance, if A is a substrate then its rate of utilization 
determines the rate of consumption of B and the rate of production of C. If C is involved 
in a single further reaction, for instance, C -> D, then the flux towards D will also be 
constrained to certain value by measurement of the uptake rate of A. Note that this 
approach only works if the rate of production and consumption of each internal 
metabolite is equal and therefore its concentration is unchanging. If the concentration of 
any internal metabolite is allowed to vary then the system can no longer be constrained 
by external fluxes and will undetermined by the data. It is for this reason that constraints-
based methods, such as FBA, can only be applied to systems in steady-state, such as 
chemostat-grown cells.  
 The first step is constraint-based approaches is to construct a metabolic network. This is 
often inferred directly from an organism’s genome annotation, which predicts genes 
encoding enzymes with defined roles in well-described biochemical conversions. These 
enzyme steps can then be incorporated into pathways and integrated into a network to 
construct a genome-scale metabolic network. Constraint based modeling approaches can 
then be applied to the model to predict the metabolic capabilities or internal fluxes [23] 
[1] [10;15;22;25], given measured constraints. There are of course limitations to these 
approaches such as the requirement for steady state conditions. Also, since no 
consideration is made of either transcriptional, translational, metabolic regulation or 
enzyme kinetics the predictive capabilities of constraint based models are limited to 
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situations when these factors are not significantly influencing reaction rates [11]. 
Nevertheless, the approach has been successfully applied to predict the metabolic 
capabilities of many different cellular systems [23] [1] [10;15;22;25] and has also been 
used in metabolic engineering to optimize production [19;24].  
Application of metabolic modeling approaches in tuberculosis is aided by the fact that 
metabolism is a reasonably well studied system even in mycobacteria. Indeed, 
metabolism has been shown to be linked to the virulence of M. tuberculosis and plays a 
key role in the development and maintenance of both acute and persistent TB infections 
[16;20;21]. It is perhaps not surprising therefore that initial modeling efforts in 
tuberculosis have focused on metabolism.  
The first M. tuberculosis constraint based model was constructed by Raman et al (2005) 
and consisted of all the reactions in mycolic acid synthesis [26]. This sub-model of 
metabolism was composed of 219 reactions which involved 197 metabolites, catalysed by 
28 enzymes. FBA was used to simulate mycolic acid metabolism and to identify seven 
potential drug targets in these pathways. Although targeting a small sub-system such as 
mycolic acid synthesis can yield valuable information on specific pathways, it has limited 
value in elucidating the metabolic capability of M. tuberculosis. This latter objective is 
best approached by constructing a genome-scale networks of metabolism [2] [17]. The 
first published genome scale network was built by our group using Streptomyces 
coelicolor as a starting model [2]. The final functional genome scale metabolic network 
of M. tuberculosis (GSMN-TB) consisted of 739 metabolites participating in 849 
reactions and involves 726 genes. The model is freely available as both an excel file or in 
sbml format; and is accessible via a user friendly web tool for constraint-based 
simulations (http://sysbio.sbs.surrey.ac.uk/tb/). FBA-based predictions of in vitro gene 
essentiality using growth rate as the objective function correlated well with predictions of 
gene essentiality obtained by global transposon mutagenesis [29], with an overall 
predictive accuracy of 78% [2].  
Quantitative validation of the model was performed using growth rate data from 
continuous culture chemostat experiments [2]. Flux variability analysis (FVA) was 
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performed to assess the in silico metabolic response of M. tuberculosis to slow growth. 
FVA is a variant of FBA which computes the range of fluxes in each reaction that are 
compatible with optimization of the objective function. The FVA predicted that whereas 
the relative fluxes through most reactions would be similar between slow and fast growth 
rate, a significant increase in flux through the isocitrate lyase reaction was expected at 
slow growth rate. This generated the hypothesis that isocitrate lyase was involved in 
mycobacterial survival at slow growth rates. Isocitrate lyase is the gating enzyme into the 
glyoxylate shunt, an anapleurotic pathway important during catabolism of substrates, 
such as fatty acids, that are incorporated as 2 carbon compounds. However, the 
glyoxylate shunt is not thought to be involved in catabolism of a 3 carbon compound, 
such as glycerol, so the prediction that isocitrate lyase was raised at slow growth rate was 
surprising. If flux through the glyoxylate shunt was indeed raised then we would expect 
to see a parallel rise in isocitrate lyase enzyme activity. This was confirmed in chemostat-
grown M. bovis BCG, supporting the hypothesis that the glyoxylate shunt is involved in 
maintenance of slow growth of the tubercle bacillus, at least in the chemostat. The 
findings may also have relevance to the demonstration that isocitrate lyase is essential for 
survival of M. tuberculosis in vivo [20;21], prompting investigation of the enzyme as a 
possible drug target [5;30].  
A second genome scale reconstruction of M. tuberculosis was published Jamshidi and 
Palsson (2007). Silicon iNj661 weighs in at 939 reactions and 661 genes and was 
constructed using several databases combined with manual curation [17]. This model was 
validated by comparing in silico predictions of growth rate and gene essentiality with 
previously published experimental data. The in silico predictions of the growth rate of M. 
tuberculosis on three different media agreed with experimental data but the model had a 
poor predictive accuracy for experimental essentiality data (55%).  
Building upon the work described by Ramen et al (2005) hard-coupled reaction (HCR) 
sets were calculated for the iNj66I model in order to predict novel drug targets on a 
genome scale [17]. Hard coupling reaction (HCR) sets are generated by a method which 
does not require an objective function and therefore overcomes any bias introduced by 
using a specific objective function to constrain the solution space. HCR’s are groups of 
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reactions which, due to mass conservation and connectivity constraints, must operate in 
unison. This strategy identified known and also potential new drug targets which require 
further analysis.  
The mycolic acid synthesis sub-model and the two genome scale network reconstructions 
available for M. tuberculosis illustrate the different approaches which can be applied to 
reconstructing, validating and applying metabolic models. They also provide a reference 
for future metabolic reconstructions. The next challenge is to combine these 3 models and 
build upon them by integrating any new experimental data in order to expand and refine 
the reconstructions in an iterative cycle. In this way the model can serve as an up-to-date 
representation of the cumulative knowledge of M. tuberculosis’s metabolic capabilities. 
For comparison, the E. coli genome scale network has undergone six different successive 
reconstructions over the last 18 years, each one contributing positively to a large number 
of different studies [15]. A well curated reconstruction is a perquisite for all systems 
biology approaches to studying M. tuberculosis. We and others are currently 
reconstructing the next generation of genome scale TB models with the ultimate goal of 
building an integrated host-pathogen metabolic network model. The currently available 
and future models will lead to many advances and are likely to provide a crucial 
component of TB research. 
Applications of the models  
The reconstruction process itself demonstrated the utility of in silico models of M. 
tuberculosis metabolism in computing phenotypic behaviour, predicting drug targets and 
in the generation of novel hypotheses, which can then be used to guide experimentation 
[2;17;26]. In addition, several groups have already applied these models with significant 
initial success to identify drug targets, model drug inhibition and also as a context for 
interpretation of experimental data [3;8;13;18;27;28].  
Metabolic models have also been used for drug discovery [7]. Raman et al (2008) have 
developed a very useful framework for drug discovery which incorporates the three 
published M. tuberculosis metabolic models as part of a comprehensive and integrated 
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scheme for drug identification. TargetTB imposes sequential filters on an initial list of 
essential genes in order to generate several shortlists of putative drug targets [28]. The 
first list was generated by combining essentiality data from a protein-protein interactome 
and FBA studies using both the available genome scale models (iNj661, GSMN-TB) and 
also the mycolic acid pathway (MAP) sub-model. This list was then filtered using 
sequence analysis to remove genes with homologues in humans; structural analysis to 
remove targets with similar binding sites to human proteins and this process identified 
622 putative drug targets. Further filtering generated a short list of broad spectrum 
antibacterial, TB specific targets and also those candidates which could be important for 
treating persistent TB (216 targets). Several known and proposed candidate drug targets 
were identified using TargetTB, validating this approach and indicating that the other 
targets on this list could also be promising candidates for subsequent experimental 
investigations.  
As an alternative to the above approaches which predict reactions as drug targets by 
evaluating their effects on metabolism, Kim et al (2009) used a metabolite-centric 
approach to identify potential candidate drug targets in a number of pathogens including 
M. tuberculosis. Their strategy was to use metabolite essentiality and chokepoint analysis 
as a starting point for prioritizing drug targets [18]. This approach has the advantage of 
identifying multiple target mechanisms which would be very computationally expensive 
by a reaction centric route. Using constraint based flux analysis of the iNj661 model, 
essential metabolites were identified as metabolites which resulted in zero growth when 
removed from the model using growth rate as the objective function. Chokepoint analysis 
identifies enzymes that uniquely produce and/or consume a particular metabolite. 
Metabolites which were both essential and chokepoints were filtered in order to remove 
metabolites with human homologues that could produce unwanted side effects. This 
analysis identified 413 essential metabolites, 554 chokepoints and a final list of 364 
putative drug targets in M. tuberculosis. Chorisomate was identified by this analysis as a 
broad range target. As a product of the shikimate pathway which is essential in higher 
plants, fungi, bacteria and algae and is absent in mammals chorisomate production has 
been validated as an attractive drug target by others [9;12]. Mycolate was also identified 
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as a prioritized drug target and its metabolism is already targeted by current anti-
tubercular drugs.   
In another study drug target combinations were identified using an iNj661 based reaction 
influence network in order to analyze protein-protein dependencies [27]. Proteins were 
identified which are highly influential in the network and their interaction with other 
influential proteins analysed in order to ascertain influential pairs, triplets and 
quadruplets. This analysis was complemented with FBA which demonstrated that most of 
the identified combinations of proteins are also synthetic lethals in silico and may 
therefore be very good drug targets.  
Future challenges 
Whilst the application of systems biology approaches to studying M. tuberculosis is still 
in the early stages, several novel approaches has delivered new insight into the 
metabolism of this pathogen. This review has illustrated that the metabolic model 
reconstruction process can in itself reveal useful information about the biology of M. 
tuberculosis [2] [17]. Ultimately these metabolic models will be complemented by the 
integration of regulatory and signaling circuits. However as this process is only just 
beginning in E. coli this is a very long term aim for TB systems biologists. While fully 
integrated models of tuberculosis are still a very distant goal, systems biology efforts can 
(and are beginning to) have an enormous impact on both our understanding of the 
metabolic potential of M. tuberculosis and the success of the drug discovery process 
which could lead to significant advances in the treatment of tuberculosis.   
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